William J. Gradishar, MD

Articles

Future Directions in Care for HER2+ Breast Cancer

August 15th 2022

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

August 15th 2022

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Novel Treatment Strategies for HER2-Low Breast Cancer

August 8th 2022

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.

Establishing the Paradigm of HER2-Low Breast Cancer

August 8th 2022

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer

August 1st 2022

Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.

HER2+ mBC: Practical Selection and Sequencing of Therapy

August 1st 2022

Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.

Novel Treatment Approaches to Brain Metastases in HER2+ Breast Cancer

July 25th 2022

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.

HER2+ Metastatic Breast Cancer: Safety Data With T-DXd

July 25th 2022

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

Overview of Treatment Options in HER2+ Metastatic Breast Cancer

July 18th 2022

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Escalation or Deescalation of Therapy in Early-Stage HER2+ Breast Cancer

July 18th 2022

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

Early-Stage HER2+ Breast Cancer: Novel Perioperative Treatment Strategies

July 11th 2022

Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.

Establishing the Role of Neratinib Therapy in Early-Stage HER2+ Breast Cancer

July 11th 2022

Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Optimizing Use of T-DM1

July 4th 2022

A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.

Subcutaneous HP Therapy in Early-Stage HER2+ Breast Cancer

July 4th 2022

Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

June 27th 2022

Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

June 27th 2022

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

Novel Chemoprotective Therapies Under Investigation

November 29th 2021

Novel agents under investigation to help address unmet needs in the field of prophylaxis against neutropenia and other toxicities associated with chemotherapies used to treat solid tumors.

CIN Treatment Advances: SIMBA Therapy

November 12th 2021

What to know about plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), in preventing chemotherapy-induced neutropenia.

Dr. Gradishar on Pretreating for Infusion Reactions in Breast Cancer and Other Malignancies

April 22nd 2021

William Gradishar, MD, discusses the importance of pretreatment to prevent drug-induced infusion reactions in patients with breast cancer and other malignancies.

Dr. Gradishar on Pretreatment With Cetirizine to Prevent Infusion Reactions in Breast Cancer and Other Malignancies

April 19th 2021

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.